BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

KINAXO Biotechnologies Extends its Collaboration with Roche (RHHBY)


1/14/2010 11:24:47 AM

Martinsried, Germany, January 12, 2010 / b3c newswire / - KINAXO Biotechnologies GmbH announced today that it has entered into a second collaboration with Roche Diagnostics GmbH in Penzberg, Germany. Under the agreement KINAXO will apply its phosphoproteomics technology PhosphoScout® to support targeted treatment approaches currently under development at Roche. Financial details of the agreement were not disclosed.

KINAXO’s phosphoproteomics platform PhosphoScout® enables the identification of regulated protein phosphorylation sites in response to therapeutic antibody or kinase inhibitor treatment. Using state-of-the-art quantitative mass spectrometry, up to 15,000 phosphorylation sites can be monitored in a single experiment, thereby facilitating analysis of the phosphoproteome in patient samples, animal models and cell culture on a global scale. Unlike immunoassays, PhosphoScout® does not require antibodies for detection, thus enabling unbiased, comprehensive phosphoproteome analyses across entire signaling pathways. This positions PhosphoScout® as an upcoming technology for drug mode of action analysis and the stratification of cancer patients receiving targeted therapies.

About KINAXO - www.kinaxo.com

KINAXO Biotechnologies is a privately-held biotechnology service company based in Munich/Martinsried, Germany.

KINAXO offers extensive experience in chemical proteomics and quantitative phosphoproteomics technologies for drug mode-of-action analysis, cellular target profiling, target deconvolution, and drug re-positioning.

KINAXO just completed a financing round and recently announced its collaboration with Bayer Vital GmbH for biomarker development, as well as renewing its ongoing agreement with Johnson & Johnson.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES